The role of bendamustine in the treatment of indolent non-Hodgkin lymphoma

References

• JemalASiegelRWardEHaoYXuJThunMJCancer statistics, 2009CA Cancer J Clin20095922524919474385
   PubMed Web of Science ®Google Scholar
• YoungRCLongoDLGlatsteinEIhdeDCJaffeESDeVitaVTJrThe treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatmentSemin Hematol19882511162456618
   PubMed Web of Science ®Google Scholar
• BricePBastionYLepageEGroupe d’Etude des Lymphomes de l’AdulteComparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d’Etude des Lymphomes FolliculairesJ Clin Oncol199715111011179060552
   PubMed Web of Science ®Google Scholar
• ArdeshnaKMSmithPNortonALong-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced- stage non-Hodgkin lymphoma: a randomized controlled trialLancet200336251652212932382
   PubMed Web of Science ®Google Scholar
• SwensonWTWooldridgeJELynchCFForman-HoffmanVLChrischillesELinkBKImproved survival of follicular lymphoma patients in the United StatesJ Clin Oncol20052344814830
   Web of Science ®Google Scholar
• MarcusRImrieKBelchACVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphomaBlood20051051417142315494430
   PubMed Web of Science ®Google Scholar
• HiddemannWKnebaMDreylingMFrontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study GroupBlood20051063725373216123223
   PubMed Web of Science ®Google Scholar
• HeroldMHaasASrockSRituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology StudyJ Clin Oncol2007251986199217420513
   PubMed Web of Science ®Google Scholar
• SallesGMounierNde GuibertSRituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 studyBlood20081124824483118799723
   PubMed Web of Science ®Google Scholar
• FriedbergJWHuangJDillonHInitial therapeutic strategy in follicular lymphoma: an analysis from the National LymphoCare studyJ Clin Oncol (Meeting Abstracts)2006247527
   Web of Science ®Google Scholar
• FisherRIKaminskiMSWahlRLTositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin’s lymphomasJ Clin Oncol2005237565757316186600
   PubMed Web of Science ®Google Scholar
• KaminskiMSTuckMEstesJ131I-tositumomab therapy as initial treatment for follicular lymphomaN Engl J Med200535244144915689582
   PubMed Web of Science ®Google Scholar
• KaminskiMSRadfordJAGregorySASouthwest Oncology GroupRetreatment with I-131 tositumomab in patients with non-Hodgkin’s lymphoma who had previously responded to I-131 tositumomabJ Clin Oncol2005237985799316204016
   PubMed Web of Science ®Google Scholar
• PressOWUngerJMBrazielRMPhase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin’s lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911J Clin Oncol2006244143414916896003
   PubMed Web of Science ®Google Scholar
• WitzigTEFlinnIWGordonLITreatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin’s lymphomaJ Clin Oncol2002203262326912149300
   PubMed Web of Science ®Google Scholar
• CorradiniPDoderoAFarinaLFaninRPatriarcaFAllogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcomeLeukemia2007212316232317597807
   PubMed Web of Science ®Google Scholar
• RezvaniARStorerBMarisMSorrorMLAguraENonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin’s lymphomaJ Clin Oncol20082621121718056679
   PubMed Web of Science ®Google Scholar
• OzegowskiWKrebsDIMET 3393, (-[1-Methyl-5-bis-(-chloroethyl)-amino-benzimidazolyl-(2)]-butyric acid hydrochloride, a new cytostatic agent from among the series of benzimidazole mustard compounds [in German]Zbl Pharm197111010131019
   Google Scholar
• SchwanenCHeckerTHubingerGIn vitro evaluation of bendamustine induced apoptosis in B-chronic lymphocytic leukemiaLeukemia2002162096210512357363
   PubMed Web of Science ®Google Scholar
• KonstantinovSMKostovskiATopashka-AnchevaMGenovaMBergerMRCytotoxic efficacy of bendamustine in human Leukemia and breast cancer cell linesJ Cancer Res Clin Oncol200212827127812029443
   PubMed Web of Science ®Google Scholar
• ChowKUBoehrerSGeduldigKIn vitro induction of apoptosis of neoplastic cells in low-grade non-Hodgkin’s lymphomas using combinations of established cytotoxic drugs with bendamustineHaematologica20018648549311410411
   PubMed Web of Science ®Google Scholar
• GaulLMandl-WeberSBaumannPEmmerichBSchmidmaierRBendamustine induces G2 cell cycle arrest and apoptosis in myeloma cells: the role of ATM-Chk2-Cdc25A and ATMp53-p21-pathwaysJ Cancer Res Clin Oncol200813424525317653574
   PubMed Web of Science ®Google Scholar
• LeoniLMBaileyBReifertJBendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agentsClin Cancer Res20081430931718172283
   PubMed Web of Science ®Google Scholar
• Forero-TorresASalehMNBendamustine in non-Hodgkin lymphoma: the double-agent that came from the Cold WarClin Lymphoma Myeloma20078S13S1718282361
   PubMedGoogle Scholar
• HartmannMZimmerCInvestigation of cross-link formation in DNA by the alkylating cytostatic IMET 3106,3393 and 3943Biochim Biophys Acta19722873863894629776
   PubMed Web of Science ®Google Scholar
• StrumbergDHarstrickADollKHoffmannBSeeberSBendamustine hydrochloride activity against doxorubicin resistant human breast carcinoma cell linesAnticancer Drugs199674154218826610
   PubMed Web of Science ®Google Scholar
• GandhiVMetabolism and mechanisms of action of bendamustine: rationales for combination therapiesSemin Oncol20022941112170425
   PubMed Web of Science ®Google Scholar
• RasschaertMSchrijversDVan den BrandeJA phase I study of bendamustine hydrochloride administered once every 3 weeks in patients with solid tumorsAnticancer Drugs20071858759517414628
   PubMed Web of Science ®Google Scholar
• RasschaertMSchrijversDVan den BrandeJA phase I study of bendamustine hydrochloride administered day 1 + 2 every 3 weeks in patients with solid tumorsBr J Cancer2007961692169817486132
   PubMed Web of Science ®Google Scholar
• CephalonIncTreanda® [prescribing information] Bendamustine hydrochloride for injection for intravenous infusionCephalon, IncFrazer (PA)20094 http://www.treanda.com/300-nhl-home.aspx.
   Google Scholar
• PreissRSohrRMatthiasMBrockmannBHüllerHThe pharmacokinetics of bendamustine (Cytostasane) in humansPharmazie1985407827844095129
   PubMed Web of Science ®Google Scholar
• MatthiasMPreissRSohrRPossingerKPharmacokinetics of bendamustine in patients with malignant tumorsJ Clin Oncol (Meeting Abstracts)1995141476
   Google Scholar
• TeichertJBaumannFChaoQCharacterization of two phase I metabolites of bendamustine in human liver microsomes and in cancer patients treated with bendamustine hydrochlorideCancer Chemother Pharmacol20075975977016957931
   PubMed Web of Science ®Google Scholar
• OwenJSMelhemMD’AndreaDDarwishMPopulation pharmacokinetics of bendamustine and metabolites in patients with indolent non-Hodgkin’s lymphoma (NHL)Pharmacol Ther200883S54S55
   Web of Science ®Google Scholar
• LissitchkovTArnaudovGPeytchevDMerkleKhPhase-I/II study to evaluate dose limiting toxicity, maximum tolerated dose, and tolerability of bendamustine HCl in pre-treated patients with B-chronic lymphocytic leukaemia (Binet stages B and C) requiring therapyJ Cancer Res Clin Oncol20061329910416292542
   PubMed Web of Science ®Google Scholar
• KopplerHHeymannsJPandorfAWeideRBendamustine plus mitoxantrone – a new effective treatment for advanced chronic lymphocytic leukaemia: Results of a phase I/II studyLeuk Lymphoma20044591191315291348
   PubMed Web of Science ®Google Scholar
• PönischWMitrouPSMerkleKTreatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone – a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO)J Cancer Res Clin Oncol200613220521216402269
   PubMed Web of Science ®Google Scholar
• von MinckwitzGChernozemskyISirakovaLBendamustine prolongs progression-free survival in metastatic breast cancer (MBC): a phase III prospective, randomized, multicenter trial of bendamustine hydrochloride, methotrexate and 5-fluorouracil (BMF) versus cyclophosphamide, methotrexate and 5-fluorouracil (CMF) as first-line treatment of MBCAnticancer Drugs20051687187716096436
   PubMed Web of Science ®Google Scholar
• WinerEGralowJDillerLClinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening – a report from the American Society of Clinical OncologyJ Clin Oncol20092781282619103723
   PubMed Web of Science ®Google Scholar
• http://www.cancer.gov/cancertopics/druginfo/fda-bendamustine-hydrochloride. Accessed on July 24, 2009.
   Google Scholar
• LeoniLMBaileyBNiemeyerCCIn vitro and ex vivo activity of SDX- 105 (bendamustine) in drug-resistant lymphoma cellsAACR Meeting Abstracts2004278-b
   Google Scholar
• ChowKUSommerladWDBoehrerSAnti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspasesHaematologica2002871334311801463
   PubMed Web of Science ®Google Scholar
• RummelMJChowKUHoelzerDMitrouPSWeidmannEIn vitro studies with bendamustine: enhanced activity in combination with rituximabSemin Oncol200229121412170426
   PubMed Web of Science ®Google Scholar
• HeiderANiederleNEfficacy and toxicity of bendamustine in patients with relapsed low-grade non-Hodgkin’s lymphomasAnticancer Drugs20011272572911593053
   PubMed Web of Science ®Google Scholar
• BremerKHigh rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin’s-lymphomasJ Cancer Res Clin Oncol20021281160360912458340
   PubMed Web of Science ®Google Scholar
• KahlBBartlettNLLeonardJPBendamustine is safe and effective in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphomaBlood ASH Annual Meeting Abstracts112007110 Abstract 1351.
   Google Scholar
• FriedbergJWCohenPChenLBendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin’s lymphoma: results from a phase ii multicenter, single-agent studyJ Clin Oncol20082620421018182663
   PubMed Web of Science ®Google Scholar
• KnaufAULissitchkovTAldaoudAPhase III study of Bendamustine compared with Chlorambucil in previously untreated patients with chronic lymphocytic leukemiaJ Clin Oncol2009824 [Epub ahead of print]
   Web of Science ®Google Scholar
• NiederleNBalleisenLHeitWBendamustine versus fludarabine as second-line treatment for patients with chronic lymphocytic leukemia – first interim results of a randomized studyAnn Oncol200819suppl 4iv192iv196 Abstract 379.
   Google Scholar
• WeideRBendamustine HCL for the treatment of relapsed indolent non-Hodgkin’s lymphomaTher Clin Risk Manag2008472773219209254
   PubMedGoogle Scholar
• HeckHKPreissJMSchmidtPBendamustine (B) and mitoxantrone (M) in the treatment of low grade non-Hodgkin’s lymphoma (NHL)J Cancer Res Clin Oncol1998124147
   Google Scholar
• KahlCHeroldMHöffkesHBendamustine, methotrexate, mitoxantrone and prednisone (BMMP) for the treatment of high grade non-Hodgkin’s lymphomaOnkologie199720406408
   Web of Science ®Google Scholar
• KönigUJunghassCDeckerSResponse of refractory and relapsed low grade non-Hodgkin’s lymphoma and chronic lymphocytic leukemia to Dexa-BID, a bendamustine hydrochloride-containing regimenAnn Oncol199910 Abstract 479.
   Google Scholar
• RuffertKTherapy of low grade non-Hodgkin’s lymphoma (NHL) with bendamustine and oral etoposideAnn Oncol199910 Abstract 452.
   Google Scholar
• HeroldMSchulzeANiederwieserDBendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin’s lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19)J Cancer Res Clin Oncol200613210511216088404
   PubMed Web of Science ®Google Scholar
• KoenigsmannMKnaufWHeroldMFludarabine and bendamustine in refractory and relapsed indolent lymphoma – a multicenter phase I/II Trial of the east german society of hematology and oncology (OSHO)Leuk Lymphoma2004451821182715223642
   PubMed Web of Science ®Google Scholar
• WeideRHeymannsJGoresAKöpplerHBendamustine mitoxantrone and rituximab (BMR): a new effective regimen for refractory or relapsed indolent lymphomasLeuk lymphoma20024332733111999564
   PubMed Web of Science ®Google Scholar
• WeideRPandorfAHeymannsJKöpplerHBendamustine/mitoxantrone/rituximab (BMR): a very effective, well tolerated outpatient chemoimmunotherapy for relapsed and refractory CD20-positive indolent malignancies. Final results of a pilot studyLeuk Lymphoma2004452445244915621757
   PubMed Web of Science ®Google Scholar
• WeideRHessGKöpplerHHigh anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG)Leuk Lymphoma2007481299130617613757
   PubMed Web of Science ®Google Scholar
• RummelMJAl-BatranSEKimSZBendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin’s lymphomaJ Clin Oncol2005233383338915908650
   PubMed Web of Science ®Google Scholar
• RobinsonKSWilliamsMEvan der JagtRHPhase II Multicenter Study of Bendamustine Plus Rituximab in Patients With Relapsed Indolent B-Cell and Mantle Cell Non-Hodgkin’s LymphomaJ Clin Oncol2008264473447918626004
   PubMed Web of Science ®Google Scholar
• RummelMJvon GrünhagenUNiederleNBendamustine plus rituximab versus CHOP plus rituximab in the first line treatment of patients with indolent and mantle cell lymphomas – randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany)Blood (ASH Annual Meeting Abstracts)112008112259618809766
   PubMed Web of Science ®Google Scholar
• RummelMJHeineKBodensteinHEfficacy and safety of bendamustine and rituximab in the treatment of indolent and mantle cell lymphomas in older patientsJ Clin Oncol (Meeting Abstracts)2008268572
   Web of Science ®Google Scholar
• FischerKStilgenbauerSSchweighoferCDBendamustine in combination with rituximab for patients with relapsed chronic lymphocytic leukemia: A multicentre phase II trial of the German CLL Study Group (GCLLSG)Blood (ASH Annual Meeting Abstracts)11200811233018451308
   PubMed Web of Science ®Google Scholar
• Schmidt-HieberMBusseAReufiBKnaufWThielEBlauIWBendamustine, but not fludarabine, exhibits a low stem cell toxicity in vitroJ Cancer Res Clin Oncol200913522723418719942
   PubMed Web of Science ®Google Scholar